• Nachrichtendetail
• 

13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

	Name	WKN	Börse	Kurs	Datum/Zeit	Diff.	Diff. %	Geld	Brief	Erster	Schluss
	SANOFI SA INHABER EO 2	920657	Xetra	89,850	28.06.24 10:07:23	-0,020	-0,02%	90,020	90,080	90,380	89,870
	REGENERON PHARMAC.DL-,001	881535	Frankfurt	976,600	28.06.24 09:24:09	-16,400	-1,65%	972,200	983,800	976,600	993,000